
Adult Outpatient COVID-19 Treatment Overview

January 2023

Southern Illinois Healthcare

The Department of Health and Human Services/ASPR has an Outpatient Therapeutics Decision Aid available as seen


below to help guide appropriate outpatient treatment. Available at: COVID-19 Therapeutics Decision Aid (hhs.gov)



DEC 2022

COVID-19 Outpatient Therapeutics

Clinical Decision Aid: Pediatric patients 28 days of age and older weighing 3 kg to less than 40 kg with mild to moderate COVID-19 and at high risk for progression to severe disease







Resources

Recommendations for the outpatient treatment of adults with mild to moderate COVID-19 continue to evolve. All guidelines are subject to change and should routinely be checked for updates.

Supply of outpatient treatments for mild to moderate COVID-19 has been variable. Resources from the NIH and IDPH include guidance on identifying patients most at risk of progressing to severe disease when supply is limited. Useful resources include:

• The National Institutes of Health (NIH) provides COVID-19 treatment guidelines that are updated regularly <u>COVID-19</u> <u>Treatment Guidelines (nih.gov)</u> and <u>Clinical Management of Adults | COVID-19 Treatment Guidelines (nih.gov)</u> The guidelines include a section on nonhospitalized adults <u>Nonhospitalized Adults: Therapeutic Management | COVID-19 Treatment Guidelines (nih.gov)</u> <u>19 Treatment Guidelines (nih.gov)</u>

• The **Illinois Department of Public Health** (IDPH) has an overview of outpatient COVID treatments on their website: <u>COVID-19 Outpatient Treatment (illinois.gov)</u>

•The **CDC** includes information on underlying conditions that place patients at higher risk of severe COVID-19 Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Professionals | CDC as well as additional guidance on the CDC website

•The **Department of Health and Human Services/ASPR** has a quick reference of therapeutics authorized or approved to prevent COVID-19 or treat mild to moderate COVID-19 <u>Side-by-Side Overview of Outpatient Therapies Authorized for Treatment of Mild-Moderate COVID-19 (hhs.gov)</u> the outpatient therapeutics decision aid as noted above <u>COVID-19</u> <u>Therapeutics Decision Aid (hhs.gov)</u> and additional information on COVID-19 therapeutics <u>COVID-19 Therapeutics |</u> <u>HHS/ASPR</u>

•The primary resources for each medication available through an EUA are the EUA documents for that medication.

Emergency Use Authorizations (EUA)

As new medications have become available for the treatment of COVID, most have been released under an EUA rather than full FDA approval. The EUA for each medication includes specific criteria that must be met for the use of the drug. **EUAs require that the patient is educated about the drug that is prescribed for them and that they receive and understand the Fact Sheet for Patients, Parents, and Caregivers specific to that medication**. Since EUA medications are not FDA approved, SIH includes consent as part of the ordering process for any EUA medication.

Treatment availability

<u>Paxlovid</u> is orderable through Epic for SIH providers and is available at retail pharmacies. Drug information is highlighted below; please see appropriate resources for complete information prior to prescribing.

<u>Outpatient Remdesivir</u> - SIH currently has no effective capacity to administer a three-day course of daily IV Remdesivir in the ambulatory setting.

<u>Molnupiravir</u> - The position of SIH is that <u>Molnupiravir</u> should not be considered for patient treatment and is not orderable through Epic due to the following concerns: limited efficacy and significant safety concerns (risks outweigh benefit); long term mutagenicity and need for contraceptive practices (9 days for females, 3 months for males). Molnupiravir is available through local outpatient pharmacies.

Antiviral Resistance

Please refer to current guidance on antiviral resistance as new variants emerge. The EUAs for COVID therapies now include language that authorization for use will change based on the patterns of resistance as new variants emerge. The FDA updates any changes in authorized geographic areas at <u>Emergency Use Authorization | FDA</u>

Highlights of Drug Information

See Complete EUAs, Resistance Patterns, and Treatment Guidelines Prior to Prescribing

Therapeutic agent	Notes	SIH Ordering and Consent Process
Paxlovid	 Available at outpatient pharmacies 	 Orderable in Epic through order set
Ritonavir-boosted nirmatrelvir	 Serious drug-drug interactions are 	with EUA criteria including
Oral antiviral combination available	possible. Before prescribing Paxlovid,	confirmation of drug interaction
through EUA for outpatient	be familiar with the drug interactions	review and documentation of
treatment of mild to moderate	as listed in the EUA and consider	patient education and consent.
COVID-19	additional guidance, such as:	
Refer to the EUA Fact Sheet for	Pfizer drug interaction checking tool:	 Confirmation of verbal consent is
Health Care Providers for complete	Drug Interaction Checker Pfizer	built into Epic ordering process
information prior to prescribing.	Medical Information - US	
The FDA has released a Paxlovid	Pfizer Paxlovid HCP website	 Dose adjustment required for
eligibility screening checklist to help	PAXLOVID [™] (nirmatrelvir tablets;	patients with moderate renal
with clinical decision making	ritonavir tablets) For HCPs	impairment, eGFR 30 to less than 60
PAXLOVID Patient Eligibility Screening	<u>(paxlovidhcp.com)</u>	ml/mi. Not recommended for
Checklist Tool for Prescribers	Liverpool online COVID-19	patients with an eGFR less than 30
(fda.gov)	Interaction website: <u>Liverpool COVID-</u>	ml/min.
 Initiate within 5 days of symptom 	19 Interactions (covid19-	
onset	druginteractions.org)	 A thorough medication history is
	NIH: Ritonavir-Boosted Nirmatrelvir	necessary, including over-the-
	(Paxlovid) COVID-19 Treatment	counter and herbal medications, to
	Guidelines (nih.gov)	avoid the potential for serious drug
	Consider expert consultation as	interactions.
	necessary.	
Bebtelovimab	 No longer authorized for use due to 	Not currently orderable through SIH
IV monoclonal antibody for	decreased effectiveness with current	
outpatient treatment of mild to	variants	
moderate COVID		
Evusheld	 No longer authorized for use due to 	Not currently orderable through SIH
Tixagevimab with cilgavimab	decreased effectiveness with current	
Monoclonal antibody injection for	variants	
preexposure prophylaxis in patients		
meeting criteria		
Remdesivir	Not available for outpatient treatment	Not orderable for outpatient use
IV antiviral medication with a three	at SIH due to logistical concerns	within SIH Epic
day dosing regimen for outpatient	Augilable for investigations at CIU for	
treatment of mild to moderate	•Available for inpatient use at SIH for	
COVID-19	moderate to severe COVID-19	
Molnupiravir	Not recommended by SIH due to	Not orderable within SIH Epic
Oral antiviral available through EUA	efficacy and safety concerns	Not orderable within Shi Epic
for outpatient treatment of mild to	cificacy and safety concerns	
moderate COVID-19		

References:

1. FDA. Emergency Use Authorizations. Available at Emergency Use Authorization | FDA

2. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at <u>https://www.covid19treatmentguidelines.nih.gov/</u>. Accessed 1-30-2023

3.COVID-10 Treatment Guidelines Panel. Therapeutic Management of Nonhospitalized Adults with COVID-19. September 26, 2022. Available at: <u>Nonhospitalized Adults: Therapeutic Management | COVID-19 Treatment Guidelines</u> (nih.gov)

4. NIH. Paxlovid Drug-Drug Interactions. September 26, 2022. Available at: <u>Paxlovid Drug-Drug Interactions | COVID-19</u> <u>Treatment Guidelines (nih.gov)</u>

5.FDA. Paxlovid Fact Sheet for Health Care Providers [Fact Sheet].

6.Gilead. Remdesivir (Veklury) Prescribing Information 2020.

7.FDA. Molnupiravir Fact Sheet for Health Care Providers [Fact Sheet].

8.FDA. Bebtelovimab Fact Sheet for Health care Providers [Fact Sheet].

9. Department of Health and Human Services -Assistant Secretary for Preparedness and Response. <u>COVID-19</u> <u>Therapeutics Decision Aid (hhs.gov)</u> Accessed 1-30-2023